How do you see the future of access, affordability, and general utilization of PCSK9 inhibitors as a result of the price reductions and results from CV outcome trials?

How do you see the future of access, affordability, and general utilization of PCSK9 inhibitors as a result of the price reductions and results from CV outcome trials?

How do you see the future of access, affordability, and general utilization of PCSK9 inhibitors as a result of the price reductions and results from CV outcome trials?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical and Preventive Cardiologist's Perspective

Presenter

R. Scott Wright, MD

R. Scott Wright, MD

Professor of Medicine Department of Cardiovascular Medicine Cardiovascular Division Mayo Clinic